Back to News
Market Impact: 0.2
Takeda Says Zasocitinib Tops Deucravacitinib With Superior Skin Clearance In Phase 3 Trial
Source: Nasdaq
Healthcare & Biotech
Takeda announced new data from three Phase 3 LATITUDE studies evaluating zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis. The article provides no efficacy, safety, or regulatory details, limiting the immediate read-through for Takeda's valuation.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
TAK0.55
More News
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Some Oura IPO Investors Were Said to Push Back Citing Valuation
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data